Home Medicine MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma
Article
Licensed
Unlicensed Requires Authentication

MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma

  • Julia Kovacova , Alexandr Poprach , Tomas Buchler , William C. Cho and Ondrej Slaby EMAIL logo
Published/Copyright: February 16, 2018
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Clinical Chemistry and Laboratory Medicine (CCLM) Volume 56 Issue 9

Abstract

Renal cell carcinoma (RCC) accounts for 2%–3% of all malignant tumours. The first-choice treatment in metastatic RCC (mRCC) patients is tyrosine kinase inhibitors (TKIs). Although TKIs may prolong survival of the treated patients who are not primary resistant, almost all of them will eventually develop secondary resistance to the treatment after a progression-free period. To predict treatment response, thus, we need efficient biomarkers for rational indication of TKIs in mRCC. MicroRNAs (miRNAs) not only play important roles in the pathogenesis of many cancers, including RCC but also have been shown to serve as promising diagnostic, prognostic and predictive biomarkers in various cancers. However, the potential of miRNAs to predict response to therapy with TKIs in mRCC has not yet gained sufficient attention. Because personalisation of the TKIs indication in mRCC presents an important unmet medical need, we summarise research on this topic and give an overall insight on the current knowledge in this field.

Keywords: miRNAs; prediction; renal cell carcinoma; sunitinib; tyrosine kinase inhibitor
Corresponding author: Assoc. Prof. Ondrej Slaby, PhD, Central European Institute of Technology, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: Supported by the Ministry of Health of the Czech Republic, grant No. 15-34678A. All rights reserved.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Le Tourneau C, Raymond E, Faivre S. Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors [GIST]. Ther Clin Risk Manag 2007;3:341–8.10.2147/tcrm.2007.3.2.341Search in Google Scholar

2. Bamias A, Escudier B, Sternberg CN, Zagouri F, Dellis A, Djavan B, et al. Current clinical practice guidelines for the treatment of renal cell carcinoma: a systematic review and critical evaluation. Oncologist 2017;22:667–79.10.1634/theoncologist.2016-0435Search in Google Scholar

3. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584–90.10.1200/JCO.2008.20.1293Search in Google Scholar

4. Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009;10:992–1000.10.1016/S1470-2045(09)70240-2Search in Google Scholar

5. Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci USA 2008;105:1516–21.10.1073/pnas.0707493105Search in Google Scholar PubMed PubMed Central

6. Fasanaro P, D’Alessandra Y, Di Stefano V, Melchionna R, Romani S, Pompilio G, et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem 2008;283:15878–83.10.1074/jbc.M800731200Search in Google Scholar PubMed PubMed Central

7. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008;15:261–71.10.1016/j.devcel.2008.07.002Search in Google Scholar PubMed PubMed Central

8. “MiRBase.” MiRBase. Accessed September 1, 2017. http://www.mirbase.org/index.shtml.Search in Google Scholar

9. Youssef YM, White NM, Grigull J, Krizova A, Samy C, Mejia-Guerrero S, et al. Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol 2011;59:721–30.10.1016/j.eururo.2011.01.004Search in Google Scholar PubMed

10. Khella HW, Butz H, Ding Q, Rotondo F, Evans KR, Kupchak P, et al. miR-221/222 are involved in response to sunitinib treatment in metastatic renal cell carcinoma. Mol Ther 2015;23:1748–58.10.1038/mt.2015.129Search in Google Scholar PubMed PubMed Central

11. Leite KR, Canavez JM, Reis ST, Tomiyama AH, Piantino CB, Sañudo A, et al. miRNA analysis of prostate cancer by quantitative real time PCR: comparison between formalin-fixed paraffin embedded and fresh-frozen tissue. Urol Oncol 2011;29:533–7.10.1016/j.urolonc.2009.05.008Search in Google Scholar PubMed

12. Faragalla H, Youssef YM, Scorilas A, Khalil B, White NM, Mejia-Guerrero S, et al. The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma. J Mol Diagn 2012;14:385–92.10.1016/j.jmoldx.2012.02.003Search in Google Scholar PubMed

13. Cho WC. Great potential of miRNAs as predictive and prognostic markers for cancer. Expert Rev Mol Diagn 2012;12:315–8.10.1586/erm.12.21Search in Google Scholar PubMed

14. Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol 2010;42:1273–81.10.1016/j.biocel.2009.12.014Search in Google Scholar PubMed

15. Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R, et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med 2012;10:55.10.1186/1479-5876-10-55Search in Google Scholar PubMed PubMed Central

16. Zhao A, Li G, Péoc’h M, Genin C, Gigante M. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol 2013;94:115–20.10.1016/j.yexmp.2012.10.005Search in Google Scholar PubMed

17. Petillo D, Kort EJ, Anema J, Furge KA, Yang XJ, Teh BT. MicroRNA profiling of human kidney cancer subtypes. Int J Oncol 2009;35:109–14.10.3892/ijo_00000318Search in Google Scholar PubMed

18. Slaby O, Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, et al. Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chromosomes Cancer 2012;51:707–16.10.1002/gcc.21957Search in Google Scholar PubMed

19. Silva-Santos RM, Costa-Pinheiro P, Luis A, Antunes L, Lobo F, Oliveira J, et al. MicroRNA profile: a promising ancillary tool for accurate renal cell tumour diagnosis. Br J Cancer 2013;109:2646–53.10.1038/bjc.2013.552Search in Google Scholar PubMed PubMed Central

20. Slaby O, Jancovicova J, Lakomy R, Svoboda M, Poprach A, Fabian P, et al. Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. J Exp Clin Cancer Res 2010;29:90.10.1186/1756-9966-29-90Search in Google Scholar PubMed PubMed Central

21. Poliseno L, Tuccoli A, Mariani L, Evangelista M, Citti L, Woods K, et al. MicroRNAs modulate the angiogenic properties of HUVECs. Blood 2006;108:3068–71.10.1182/blood-2006-01-012369Search in Google Scholar PubMed

22. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653–60.10.1038/nm0603-653Search in Google Scholar PubMed

23. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327–37.Search in Google Scholar

24. Würdinger T, Tannous BA, Saydam O, Skog J, Grau S, Soutschek J, et al. miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell 2008;14:382–93.10.1016/j.ccr.2008.10.005Search in Google Scholar PubMed PubMed Central

25. Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008;132:875–86.10.1016/j.cell.2008.02.019Search in Google Scholar PubMed PubMed Central

26. Kuhnert F, Mancuso MR, Hampton J, Stankunas K, Asano T, Chen C-Z, et al. Attribution of vascular phenotypes of the murine Egfl7 locus to the microRNA miR-126. Development 2008;135:3989–93.10.1242/dev.029736Search in Google Scholar PubMed

27. Fish JE, Santoro MM, Morton SU, Yu S, Yeh R-F, Wythe JD, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008;15:272–84.10.1016/j.devcel.2008.07.008Search in Google Scholar PubMed PubMed Central

28. Turchinovich A, Cho WC. The origin, function and diagnostic potential of extracellular microRNA in human body fluids. Front Genet 2014;5:30.10.3389/978-2-88919-242-7Search in Google Scholar

29. García-Donas J, Beuselinck B, Inglada-Pérez L, Graña O, Schöffski P, Wozniak A, et al. Deep sequencing reveals microRNAs predictive of antiangiogenic drug response. JCI Insight [Internet]. 1. [accessed 2017 Aug 26]. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5033860/.10.1172/jci.insight.86051Search in Google Scholar PubMed PubMed Central

30. Berkers J, Govaere O, Wolter P, Beuselinck B, Schöffski P, van Kempen LC, et al. A possible role for microRNA-141 down- regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-to-mesenchymal transition and hypoxia resistance. J Urol 2013;189:1930–8.10.1016/j.juro.2012.11.133Search in Google Scholar PubMed

31. Gámez-Pozo A, Antón-Aparicio LM, Bayona C, Borrega P, Gallegos Sancho MI, García-Domínguez R, et al. MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients. Neoplasia 2012;14:1144–52.10.1593/neo.12734Search in Google Scholar PubMed PubMed Central

32. Prior C, Perez-Gracia JL, Garcia-Donas J, Rodriguez-Antona C, Guruceaga E, Esteban E, et al. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma. PLoS One 2014;9:e86263.10.1371/journal.pone.0086263Search in Google Scholar PubMed PubMed Central

33. Merhautova J, Hezova R, Poprach A, Kovarikova A, Radova L, Svoboda M, et al. miR-155 and miR-484 are associated with time to progression in metastatic renal cell carcinoma treated with sunitinib [Internet]. BioMed Res Int 2015 [cited 2017 Aug 26]. Available from: https://www.hindawi.com/journals/bmri/2015/941980/.10.1155/2015/941980Search in Google Scholar PubMed PubMed Central

34. PubMed Help [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2005-. PubMed Help. [Updated 2017 Aug 29]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK3827/.Search in Google Scholar

35. Heinzelmann J, Henning B, Sanjmyatav J, Posorski N, Steiner T, Wunderlich H, et al. Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J Urol 2011;29:367–73.10.1007/s00345-010-0633-4Search in Google Scholar PubMed

36. White NM, Bao TT, Grigull J, Youssef YM, Girgis A, Diamandis M, et al. miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. J Urol 2011;186: 1077–83.10.1016/j.juro.2011.04.110Search in Google Scholar PubMed

37. Teixeira AL, Ferreira M, Silva J, Gomes M, Dias F, Santos JI, et al. Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients. Tumor Biol 2014;35:4057–66.10.1007/s13277-013-1531-3Search in Google Scholar PubMed

Received: 2017-09-24
Accepted: 2018-01-08
Published Online: 2018-02-16
Published in Print: 2018-08-28

©2018 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorials
  3. Clinical Chemistry and Laboratory Medicine continues to shine brightly in the constellation of laboratory medicine
  4. The Theranos saga and the consequences
  5. Innovative approaches in diabetes diagnosis and monitoring: less invasive, less expensive… but less, equally or more efficient?
  6. Reviews
  7. Exploring the microbiota to better understand gastrointestinal cancers physiology
  8. Linking type 2 diabetes and gynecological cancer: an introductory overview
  9. Mini Reviews
  10. MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma
  11. Salivary biomarkers and cardiovascular disease: a systematic review
  12. Opinion Paper
  13. The meteoric rise and dramatic fall of Theranos: lessons learned for the diagnostic industry
  14. General Clinical Chemistry and Laboratory Medicine
  15. Uncertainty evaluation in clinical chemistry, immunoassay, hematology and coagulation analytes using only external quality assessment data
  16. Measurement uncertainty and metrological traceability of whole blood cyclosporin A mass concentration results obtained by UHPLC-MS/MS
  17. Computer-assisted interventions in the clinical laboratory process improve the diagnosis and treatment of severe vitamin B12 deficiency
  18. Trueness, precision and stability of the LIAISON 1-84 parathyroid hormone (PTH) third-generation assay: comparison to existing intact PTH assays
  19. Fibroblast growth factor 23 and renal function among young and healthy individuals
  20. Optimizing charge state distribution is a prerequisite for accurate protein biomarker quantification with LC-MS/MS, as illustrated by hepcidin measurement
  21. Quantification of human complement C2 protein using an automated turbidimetric immunoassay
  22. EE score: an index for simple differentiation of homozygous hemoglobin E and hemoglobin E-β0-thalassemia
  23. Reference Values and Biological Variations
  24. Algorithm on age partitioning for estimation of reference intervals using clinical laboratory database exemplified with plasma creatinine
  25. A simple transformation independent method for outlier definition
  26. Cancer Diagnostics
  27. Quantification of vanillylmandelic acid, homovanillic acid and 5-hydroxyindoleacetic acid in urine using a dilute-and-shoot and ultra-high pressure liquid chromatography tandem mass spectrometry method
  28. Cardiovascular Diseases
  29. Sialylated isoforms of apolipoprotein C-III and plasma lipids in subjects with coronary artery disease
  30. Diabetes
  31. Analysis of protein glycation in human fingernail clippings with near-infrared (NIR) spectroscopy as an alternative technique for the diagnosis of diabetes mellitus
  32. Letter to the Editor
  33. Preanalytical errors before and after implementation of an automatic blood tube labeling system in two outpatient phlebotomy centers
  34. Hemolysis interference studies: freeze method should be used in the preparation of hemolyzed samples
  35. The curious case of postprandial glucose less than fasting glucose: little things that matter much
  36. Finding best practice in internal quality control procedures using external quality assurance performance
  37. Evaluation of the analytical performance of a new ADVIA immunoassay using the Centaur XPT platform system for the measurement of cardiac troponin I
  38. Reference ranges of the Sebia free light chain ratio in patients with chronic kidney disease
  39. Antigen excess detection by automated assays for free light chains
  40. Multiple myeloma and macro creatine kinase type 1: the first case report
  41. Comparison of five cell-free DNA isolation methods to detect the EGFR T790M mutation in plasma samples of patients with lung cancer
  42. Can we use a point-of-care blood gas analyzer to measure the lactate concentration in cerebrospinal fluid of patients with suspected meningitis?
  43. Unstable haemoglobin variant Hb Leiden is detected on Sysmex XN-Series analysers
  44. Congress Abstracts
  45. 59th National Congress of the Hungarian Society of Laboratory Medicine
https://doi.org/10.1515/cclm-2017-0861
Keywords for this article
miRNAs; prediction; renal cell carcinoma; sunitinib; tyrosine kinase inhibitor

Articles in the same Issue

  1. Frontmatter
  2. Editorials
  3. Clinical Chemistry and Laboratory Medicine continues to shine brightly in the constellation of laboratory medicine
  4. The Theranos saga and the consequences
  5. Innovative approaches in diabetes diagnosis and monitoring: less invasive, less expensive… but less, equally or more efficient?
  6. Reviews
  7. Exploring the microbiota to better understand gastrointestinal cancers physiology
  8. Linking type 2 diabetes and gynecological cancer: an introductory overview
  9. Mini Reviews
  10. MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma
  11. Salivary biomarkers and cardiovascular disease: a systematic review
  12. Opinion Paper
  13. The meteoric rise and dramatic fall of Theranos: lessons learned for the diagnostic industry
  14. General Clinical Chemistry and Laboratory Medicine
  15. Uncertainty evaluation in clinical chemistry, immunoassay, hematology and coagulation analytes using only external quality assessment data
  16. Measurement uncertainty and metrological traceability of whole blood cyclosporin A mass concentration results obtained by UHPLC-MS/MS
  17. Computer-assisted interventions in the clinical laboratory process improve the diagnosis and treatment of severe vitamin B12 deficiency
  18. Trueness, precision and stability of the LIAISON 1-84 parathyroid hormone (PTH) third-generation assay: comparison to existing intact PTH assays
  19. Fibroblast growth factor 23 and renal function among young and healthy individuals
  20. Optimizing charge state distribution is a prerequisite for accurate protein biomarker quantification with LC-MS/MS, as illustrated by hepcidin measurement
  21. Quantification of human complement C2 protein using an automated turbidimetric immunoassay
  22. EE score: an index for simple differentiation of homozygous hemoglobin E and hemoglobin E-β0-thalassemia
  23. Reference Values and Biological Variations
  24. Algorithm on age partitioning for estimation of reference intervals using clinical laboratory database exemplified with plasma creatinine
  25. A simple transformation independent method for outlier definition
  26. Cancer Diagnostics
  27. Quantification of vanillylmandelic acid, homovanillic acid and 5-hydroxyindoleacetic acid in urine using a dilute-and-shoot and ultra-high pressure liquid chromatography tandem mass spectrometry method
  28. Cardiovascular Diseases
  29. Sialylated isoforms of apolipoprotein C-III and plasma lipids in subjects with coronary artery disease
  30. Diabetes
  31. Analysis of protein glycation in human fingernail clippings with near-infrared (NIR) spectroscopy as an alternative technique for the diagnosis of diabetes mellitus
  32. Letter to the Editor
  33. Preanalytical errors before and after implementation of an automatic blood tube labeling system in two outpatient phlebotomy centers
  34. Hemolysis interference studies: freeze method should be used in the preparation of hemolyzed samples
  35. The curious case of postprandial glucose less than fasting glucose: little things that matter much
  36. Finding best practice in internal quality control procedures using external quality assurance performance
  37. Evaluation of the analytical performance of a new ADVIA immunoassay using the Centaur XPT platform system for the measurement of cardiac troponin I
  38. Reference ranges of the Sebia free light chain ratio in patients with chronic kidney disease
  39. Antigen excess detection by automated assays for free light chains
  40. Multiple myeloma and macro creatine kinase type 1: the first case report
  41. Comparison of five cell-free DNA isolation methods to detect the EGFR T790M mutation in plasma samples of patients with lung cancer
  42. Can we use a point-of-care blood gas analyzer to measure the lactate concentration in cerebrospinal fluid of patients with suspected meningitis?
  43. Unstable haemoglobin variant Hb Leiden is detected on Sysmex XN-Series analysers
  44. Congress Abstracts
  45. 59th National Congress of the Hungarian Society of Laboratory Medicine
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 22.12.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2017-0861/html
Scroll to top button